Terminated PHASE2 INTERVENTIONAL 2-arm NCT01314092

Clinical Trials of Autologous Cultured Adipose-derived Stem Cells (ANTG-ASC) on Complex Fistula (ANTG-ASC-210)

Phase II Study to Evaluate Efficacy and Safety of ANTG-ASC (Autologous Cultured Adipose-derived Stem Cells) on the Complex Fistula Patients

Sponsor: Anterogen Co., Ltd.

Conditions Complex Perianal Fistula

Interventions Autologous cultured adipose derived stem cells(high dose group) Autologous cultured adipose derived stem cells(low dose group)

Updated 6 times since 2017 Last updated: Nov 21, 2016 Started: Jan 31, 2011 Primary completion: Sep 30, 2014 Completion: Sep 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Difficulty recruiting subjects.

Other terminated trials from Anterogen Co., Ltd.

More terminations from Anterogen Co., Ltd.

Listed as NCT01314092, this PHASE2 trial focuses on Complex Perianal Fistula and remains terminated or withdrawn. Sponsored by Anterogen Co., Ltd., it has been updated 6 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Anterogen Co., Ltd.

Data source: Anterogen Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bucheon-si, South Korea
• Seoul, South Korea